CLOs on the Move

Janssen

www.janssen.com

 
Janssen, a pharmaceutical company of Johnson & Johnson, has been an innovator in the Canadian healthcare industry for over 50 years. We are guided by Our Credo, where our first responsibility is to the doctors, nurses and patients, and mothers and fathers, and all others who use our products and services. Our ultimate goal is to help people live healthy lives.
  • Number of Employees: 50K-100K
  • Annual Revenue: > $1 Billion
  • www.janssen.com
  • 1125 Trenton Harbourton Rd
    Titusville, NJ USA 08560
  • Phone: 732.524.0400

Executives

Name Title Contact Details
Vickie Mccormick
VP, North America Commercial Health Care Compliance and CIA Operations Profile
Bethany Paxson
Vice President, North America Regulatory Affairs Oncology and Diagnostics Profile

Similar Companies

Acatris

Acatris Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

ViiV Healthcare

ViiV Healthcare is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioBlast Pharma

BioBlast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The Company is building a diverse portfolio of product candidates with the potential to address unmet medical needs for incurable diseases. The BioBlast platforms are based on deep understandings of the disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology.

Quorum Review

Quorum Review IRB is an AAHRPP accredited ethics review board. Our mission is to protect patient safety while providing best-in-class customer service.

OnKure Therapeutics

OnKure, Inc. is a biopharmaceutical company focused on the discovery and development of targeted small molecule drugs to improve the outcomes of patients afflicted with cancer. OnKure`s drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized.